Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
List of Drugs for an Urgent Public Health Need - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 207873
Later capture
List of Drugs for an Urgent Public Health Need - Canada.ca
Jan 2, 2026
hc-20260101
ID 428658
updated2 sections changed; 1 added; 1 removed
2 sections changed1 added1 removed+22 / -9 linesChange ratio: 21%
--- +++ @@ -4,7 +4,7 @@ A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for a period of 1 year. If a notification has not been renewed by a public health official within one year of the initial notification, the drug will no longer be eligible for importation and sale. Drugs may also be removed from the List at any time at the Minister's discretion. A drug is only eligible for importation and sale if all columns on the List are populated, including columns located under the "For Information Purposes" subheading. (-PDF Version - 141 KB, 1 page+PDF Version - 211 KB, 1 page ) List of Drugs for an Urgent Public Health Need Brand name@@ -15,10 +15,8 @@ Foreign identifying code or number For Information Purposes Foreign regulatory authority/ Foreign country-Canadian jurisdiction notifying for the drug-/Date of notification by a public health official-Urgent public health need --Applicable Foreign Authorised Indication (Intended use or purpose of the drug)+Canadian jurisdiction notifying for the drug/Date of notification by a public health official+Urgent public health need - Applicable Foreign Authorised Indication (Intended use or purpose of the drug) Priftin Rifapentine Tablet@@ -46,12 +44,28 @@ 1 Important foreign identified risk information-see footnote below Public Health Agency of Canada - for use in all jurisdictions/-January 15, 2025+November 28, 2025 Tuberculosis crisis – For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease.-Footnotes+Rifampin for Injection, USP+Rifampin+Powder+600 mg/vial+Intravenous+63323-351-20+FDA/USA+Footnote+1+Important foreign identified risk information-see footnote below+Public Health Agency of Canada – for use in all jurisdictions/+June 30, 2025+Tuberculosis crisis –+Rifampin for injection is indicated in the treatment of all forms of tuberculosis, including the initial treatment and re-treatment of tuberculosis when the drug cannot be taken by mouth. It is also indicated for the treatment of asymptomatic carriers of+Neisseria meningitidis+to eliminate meningococci from the nasopharynx.+Footnote Footnote 1 Foreign Identified Risk: Rifapentine has been identified by the US FDA as one of the drugs that contains nitrosamine impurities. For more information, please visit the US FDA website: https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine@@ -63,5 +77,4 @@ Notification of Urgent Public Health Need Form Notification of Importation Form Page details-Date modified:-2025-04-08+2025-12-05